ES2131107T3 - Anticuerpos obtenidos mediante ingenieria genetica. - Google Patents

Anticuerpos obtenidos mediante ingenieria genetica.

Info

Publication number
ES2131107T3
ES2131107T3 ES93905306T ES93905306T ES2131107T3 ES 2131107 T3 ES2131107 T3 ES 2131107T3 ES 93905306 T ES93905306 T ES 93905306T ES 93905306 T ES93905306 T ES 93905306T ES 2131107 T3 ES2131107 T3 ES 2131107T3
Authority
ES
Spain
Prior art keywords
genetic engineering
antibodies
antibodies obtained
antiidiotipic
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93905306T
Other languages
English (en)
Inventor
Norman Hardman
Gerd Pluschke
Brendan Murray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2131107T3 publication Critical patent/ES2131107T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
    • F02B—INTERNAL-COMBUSTION PISTON ENGINES; COMBUSTION ENGINES IN GENERAL
    • F02B75/00—Other engines
    • F02B75/02—Engines characterised by their cycles, e.g. six-stroke
    • F02B2075/022—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle
    • F02B2075/027—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle four
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Abstract

LA INVENCION SE REFIERE A ANTICUERPOS ANTIIDIOTIPICOS QUE COMPRENDEN REGIONES CONSTANTES HUMANAS Y REGIONES VARIABLES DE MURINA QUE CONTIENEN LA IMAGEN INTERNA DE UN ANTIGENO ASOCIADO A LA MELANOMA DE ALTO PESO MOLECULAR HUMANA Y DERIVADOS DE LOS MISMOS QUE TIENEN LA ESPECIFICIDAD DE DICHO ANTICUERPO. ESTOS ANTICUERPOS MONOCLONALES ANTIIDIOTIPICOS Y SUS DERIVADOS TIENEN FUNCIONES INMUNORREGULADORAS Y POR TANTO SE PUEDEN UTILIZAR CON FINES DE DIAGNOSTICO Y TERAPEUTICOS, TALES COMO EL TRATAMIENTO DE MELANOMAS.
ES93905306T 1992-03-17 1993-03-05 Anticuerpos obtenidos mediante ingenieria genetica. Expired - Lifetime ES2131107T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP92810188 1992-03-17

Publications (1)

Publication Number Publication Date
ES2131107T3 true ES2131107T3 (es) 1999-07-16

Family

ID=8211884

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93905306T Expired - Lifetime ES2131107T3 (es) 1992-03-17 1993-03-05 Anticuerpos obtenidos mediante ingenieria genetica.

Country Status (12)

Country Link
US (1) US5866124A (es)
EP (1) EP0640131B1 (es)
JP (1) JPH07504802A (es)
AT (1) ATE179210T1 (es)
AU (1) AU673347B2 (es)
CA (1) CA2130173A1 (es)
DE (1) DE69324579T2 (es)
DK (1) DK0640131T3 (es)
ES (1) ES2131107T3 (es)
GR (1) GR3030702T3 (es)
MX (1) MX9301500A (es)
WO (1) WO1993019180A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06506947A (ja) * 1991-04-18 1994-08-04 マウント　シナイ　スクール　オブ　メディスン　オブ　ザ　シティー　ユニバーシティー　オブ　ニューヨーク 抗ウィルスハイブリッド抗体
EP0674907A3 (en) * 1994-03-21 1996-03-13 Ciba Geigy Ag Antibody-carrier protein conjugates, for use in active immunotherapy.
DE19911329A1 (de) * 1998-03-27 2000-09-21 Benes Ivan Friedrich Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US7468254B2 (en) * 2003-01-21 2008-12-23 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
MY148646A (en) 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
US20060223096A1 (en) * 2005-03-25 2006-10-05 Glycart Biotechnology Ag Antigen binding molecules directed to MCSP and having increased Fc receptor binding affinity and effector function
RU2006112025A (ru) * 2005-12-16 2007-10-27 Хелт Рисерч Инк. (Us) Пептиды для стимуляции иммунного ответа против меланомы
JP5836125B2 (ja) * 2008-10-16 2015-12-24 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 高分子量メラノーマ関連抗原に対する完全ヒト抗体およびその使用
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
BR112013031892A2 (pt) 2011-06-13 2016-11-22 Abgenomics Cooperatief Ua anticorpos anti-psgl-1 e seu uso
EP2764025B1 (en) 2011-10-04 2017-11-29 IGEM Therapeutics Limited Ige-antibodies against hmw-maa
CA2960756C (en) 2014-09-15 2023-08-01 Amgen Inc. Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
KR20200139720A (ko) 2018-04-02 2020-12-14 암젠 인크 에레누맙 조성물 및 이의 용도
CN115349490B (zh) * 2022-07-14 2024-01-12 成都中医药大学 一种卵巢储备功能低下动物模型的建立方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0141783B2 (en) * 1983-11-07 1993-06-16 The Wistar Institute Immune response to tumours and viruses induced by anti-idiotype antibodies
US4918164A (en) * 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
ATE115412T1 (de) * 1988-05-17 1994-12-15 Soldano Ferrone Anti-idiotyp-antikörper gegen antimenschliche hochmolekulare, an melanomen assoziierte antigene.
AU639719B2 (en) * 1989-09-15 1993-08-05 Tanox Biosystems, Inc. Treatment of autoimmune disease
ES2081963T3 (es) * 1989-11-14 1996-03-16 New York Medical College Nuevos anticuerpos monoclonales antiidiotipicos.

Also Published As

Publication number Publication date
DE69324579D1 (de) 1999-05-27
DK0640131T3 (da) 1999-11-01
EP0640131B1 (en) 1999-04-21
ATE179210T1 (de) 1999-05-15
DE69324579T2 (de) 1999-09-23
GR3030702T3 (en) 1999-11-30
MX9301500A (es) 1993-12-01
CA2130173A1 (en) 1993-09-30
AU673347B2 (en) 1996-11-07
EP0640131A1 (en) 1995-03-01
JPH07504802A (ja) 1995-06-01
US5866124A (en) 1999-02-02
AU3631393A (en) 1993-10-21
WO1993019180A1 (en) 1993-09-30

Similar Documents

Publication Publication Date Title
ES2131107T3 (es) Anticuerpos obtenidos mediante ingenieria genetica.
AR021849A1 (es) Composiciones y metodos para la inmunoterapia especifica de wt1
CY1107708T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης
DE69529649D1 (de) Anti-egfr einkettige fvs und anti-egfr antikoerper
DK0403156T3 (da) Forbedrede monoklonale antistoffer mod den humane alfa/beta-T-cellereceptor samt fremstilling og anvendelse deraf
DK0595838T3 (da) Tumorafstödningsantigenprecursorer, tumorafstödningsantigener og anvendelser deraf
NL300350I1 (nl) Geneesmiddelen met monoclonale antilichamen, die specifiek zijn voor de menselijk epidermale groeifactorreceptor
DE3887675T2 (de) Antikörper.
DE69434097D1 (de) Apoptose induzierender monoklonaler antikörper
MX9704897A (es) Secuencias del anticuerpo anti-idiotipo monoclonal recombinante 3h1 relacionadas con el antigeno carcinoembrionico humano.
DK0807125T3 (da) Monoklonale antistoffer mod CD6 til behandling og diagnosticering af psoriasis
ES2126145T3 (es) Redireccionamiento de anticuerpos.
ATE71410T1 (de) Tumorspezifische monoklonale antikoerper.
MX9306220A (es) Ptp 1d: una proteina tirosina fosfatasa novedosa.
FR2516794B1 (fr) Nouveaux medicaments anticancereux pour le traitement des leucemies t constitues de la chaine a de la ricine et d'un anticorps monoclonal specifique
ATE466031T1 (de) Anti-hgf-r-antikörper und deren verwendung
ITRM920457A0 (it) Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteinaumana.
DK0802924T3 (da) Lægemiddel til forlænget immunsuppression og eliminering af tumorceller
ES2164914T3 (es) Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
DE69127947T2 (de) Monoklonale Antikörper gegen menschliches IgE
ES2053637T3 (es) Anticuerpos monoclonales de sustancia que enlaza antitrombina y sus usos.
ES2056919T3 (es) Anticuerpo monoclonal especifico para la fosfolipasa a2 pancreatica humana.
ES2081963T3 (es) Nuevos anticuerpos monoclonales antiidiotipicos.
DK1039931T3 (da) Multivalente rekombinante antistoffer til at behandle HRV infektioner
ES521661A0 (es) Procedimiento para la preparacion continua de poliester de alto peso molecular.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 640131

Country of ref document: ES